Cullinan Therapeutics (NASDAQ:CGEM – Get Free Report) and Precision BioSciences (NASDAQ:DTIL – Get Free Report) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, dividends, institutional ownership, earnings, analyst recommendations, profitability and valuation.
Risk and Volatility
Cullinan Therapeutics has a beta of -0.11, meaning that its stock price is 111% less volatile than the S&P 500. Comparatively, Precision BioSciences has a beta of 1.11, meaning that its stock price is 11% more volatile than the S&P 500.
Analyst Ratings
This is a summary of current ratings for Cullinan Therapeutics and Precision BioSciences, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Cullinan Therapeutics | 1 | 1 | 6 | 0 | 2.63 |
| Precision BioSciences | 1 | 0 | 2 | 0 | 2.33 |
Valuation & Earnings
This table compares Cullinan Therapeutics and Precision BioSciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Cullinan Therapeutics | N/A | N/A | -$167.38 million | ($3.31) | -3.13 |
| Precision BioSciences | $68.70 million | 0.82 | $7.17 million | ($8.40) | -0.50 |
Precision BioSciences has higher revenue and earnings than Cullinan Therapeutics. Cullinan Therapeutics is trading at a lower price-to-earnings ratio than Precision BioSciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Cullinan Therapeutics and Precision BioSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Cullinan Therapeutics | N/A | -41.58% | -39.31% |
| Precision BioSciences | -11,977.36% | -233.77% | -78.93% |
Institutional & Insider Ownership
86.3% of Cullinan Therapeutics shares are owned by institutional investors. Comparatively, 38.0% of Precision BioSciences shares are owned by institutional investors. 6.1% of Cullinan Therapeutics shares are owned by insiders. Comparatively, 4.0% of Precision BioSciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Summary
Cullinan Therapeutics beats Precision BioSciences on 8 of the 13 factors compared between the two stocks.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.
About Precision BioSciences
Precision BioSciences, Inc., an advanced gene editing company, develops in vivo gene editing therapies for gene edits, including gene elimination, insertion, and excision in the United States. The company offers ARCUS, a genome editing platform to DNA genome insertion, deletion, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; PBGENE-PMM for the treatment of m.3243 associated primary mitochondrial myopathy (PMM) which is expected to submit an IND and/or CTA. In addition, it develops PBGENE-NVS for sickle cell disease/beta thalassemia for insertion; PBGENE-DMD (excision) for duchenne muscular dystrophy; PBGENE-LL2 (insertion), a liver directed target; PBGENE-LL3, a central nervous system directed target; and iECURE-OTC (insertion) for ornithine transcarbamylase deficiency. The company has license and collaboration agreement with Caribou Biosciences, Inc.; license agreement with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azer-cel for autoimmune diseases and other indications outside of cancer; development and license agreement with Eli Lilly and Company for the research and development of potential in vivo therapies for genetic disorders; Cellectis S.A.; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; Duke University; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Receive News & Ratings for Cullinan Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cullinan Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
